(EMAILWIRE.COM, July 24, 2006 ) Haifa, Israel -- The amount of engrafted cells was two hundred to four hundred percent more in a pre-clinical animal model study when the revolutionary new PLX-1 stem cell technology was transplanted together with human umbilical cord blood stem cell samples. PLX-1 consists of propagated mesenchymal stem cells that could be co-transplanted along with the hematopoietic stem cells to significantly improve the engraftment rate. Pluristem Life Systems, Inc. (OTCBB:PLRS) announces, as a result of this study, their breakthrough PLX-I stem cell product could lead to wider use in bone marrow transplants of various types of blood cancer if additional animal studies and human clinical trials prove as equally successful.

About Pluristem
Pluristem Life Systems, Inc., incorporated in Nevada, is a cell therapy company dedicated to the commercialization of stem cell therapy products for the treatment of severe blood disorders. Pluristem is discovering and developing cell-based theraputics utilizing adult stem cells expanded in a proprietary bio-reactor that mimics different naturally-occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation to treat blood cancer and other blood disorders.

Safe Harbor Statement
This news release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: a revolutionary pre-clinical animal model study showed that when the new PLX-1 stem cell technology was transplanted together with human umbilical cord blood stem cell samples the amount of engrafted cells was increased 2-4 times, PLX-1 consists of propagated mesenchymal stem cells that could be co-transplanted along with the hematopoietic stem cells to significantly improve the engraftment rate, as a result of this study, Pluristem's breakthrough PLX-I stem cell product could lead to wider use of bone marrow transplants in various types of blood cancer if additional animal studies and human clinical trials prove as equally successful, Pluristem is discovering and developing cell-based therapeutics utilizing adult stem cells expanded in a proprietary bio-reactor that mimics different naturally-occurring physiological environments, and Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation to treat blood cancer and other blood disorders. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

More information: www.pluristem.com

Media Contact
Jerry Jennings
Emerson Gerard Associates, Inc.
West Palm Beach, FL
561-881-7318
mediareply@emersongerard.com

Contact Information:
Pluristem
Gerard Jennings
Tel:
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.